Menu
Search
|

Menu

Close
X

Axsome Therapeutics Inc AXSM.OQ (NASDAQ Stock Exchange Global Market)

2.60 USD
-0.03 (-0.95%)
As of 3:59 PM EST
chart
Previous Close 2.62
Open 2.65
Volume 36,517
3m Avg Volume 51,351
Today’s High 2.67
Today’s Low 2.60
52 Week High 6.45
52 Week Low 2.47
Shares Outstanding (mil) 25.45
Market Capitalization (mil) 66.80
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-0.982
FY16
-1.420
FY15
-0.807
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.64
Price to Sales (TTM)
vs sector
--
8.67
Price to Book (MRQ)
vs sector
3.69
5.21
Price to Cash Flow (TTM)
vs sector
--
26.03
Total Debt to Equity (MRQ)
vs sector
59.93
15.38
LT Debt to Equity (MRQ)
vs sector
43.80
12.01
Return on Investment (TTM)
vs sector
-110.09
13.57
Return on Equity (TTM)
vs sector
-128.12
15.19

EXECUTIVE LEADERSHIP

Herriot Tabuteau
Chairman of the Board, Chief Executive Officer, Since 2012
Salary: $250,000.00
Bonus: $125,000.00
John Golubieski
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Constance Ames
Vice President - Finance, Since 2015
Salary: --
Bonus: --
Mark Jacobson
Senior Director - Operations, Since 2014
Salary: --
Bonus: --
Randall Kaye
Chief Medical Officer, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

25 Broadway Fl 9
NEW YORK   NY   10004-1058

Phone: +1212.2035072
Site: axsome.com/

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).

SPONSORED STORIES